에 대한 최신 뉴스 Paysafe (NYSE:PSFE) 주식

Paysafe

Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.

benzinga_deal_dispatch2

Entertainment

Asset Sales

Media

AMPS

BLCO

GRAB

NSANY

PCHM

PSFE

Sony Group Corporation American Depositary Shares

SONY

TYO:4188

블록에 등장한 신규 기업들팜켐(OTC:PCHM), 약물 감지 땀 패치의 대표 기업이 전략적 대안을 모색하고 있다(즉, 인수합병 또는 매각). 이사회는 지금까지 은행가를 고용하는 것보다 독자적으로 상황을 처리할 수 있다고 자신감을 나타냈다. 관심 있는 인수자는 공식 데이터룸에 접근할 수 있다.

딜 디스패치: 팜켐이 독자 매각을 진행, TGI 프라이데이는 $1,900만 에 19개의 레스토랑 매각

Wall Street US stocks

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

KYTX

RMBL

화요일 오전(현지 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자들의 관심을 끌 수 있는 주식 중 일부는 다음과 같다: 월가는 홈 디포(NYSE:HD)가 개장 전에 분기별 이익을 주당 4.50달러, 매출 433억 8천만 달러로 보고할 것으로 예상하고 있다. 홈디포 주가는 시간외 거래에서 0.2% 상승한 346.59달러를 기록했다.

화요일 주목해야 할 주식: 홈 디포, 페이세이프 그리고 3종목

Paysafe Ltd

Paysafe Limited Warrants, exercisable for one Common Share of Paysafe Limited at a price of $11.50 per share

BWS Financial analyst Hamed Khorsand maintains Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) with a Buy and maintains $440 price target.

Price Target

Analyst Ratings

BWS Financial Maintains Buy on Ubiquiti, Maintains $440 Price Target

Earnings Beats

LINC

UPDATE: Lincoln Educational Servs Q1 Adj. EPS $0.11 Beats $0.04 Estimate,

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1.png" alt="" class="wp-image-12780" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The company, which focuses on large language models for enterprise clients, has raised 2 billion yuan this year, from mostly government sources
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Zhipu AI is aiming to become the first of China's "AI tigers" to go public, as its competitors pivot away from costly foundational model development</li>
<li>The company relies heavily on government support, but such a strategy also carries risks, as other AI leaders have learned</li>
</ul>
Recognition or general knowledge?
That's the question confronting China's bumper crop of AI startups these days, as they try to chart a path that keeps them clear of controversy and overreliance on state support while also providing strong growth potential. While many of the earliest players focused on recognition AI that has found one of its biggest applications in surveillance, a newer generation of startups is finding bigger potential – and less controversy – in knowledge-based large language models (LLMs) like those from OpenAI and, more recently, DeepSeek.
Now, one of those,&nbsp;Zhipu AI,&nbsp;is aiming to become the first among a new group of pure LLM companies to go public, taking its first step towards an IPO by filing documentation with the Beijing Securities Regulatory Bureau last month,&nbsp;<a href="https://www.caixin.com/2025-04-15/102309642.html">according to</a>&nbsp;financial media Caixin. If the process goes smoothly, Zhipu could become the first of China's six " AI tigers" raised on knowledge-based LLMs to tap the public capital markets.
The company is widely regarded as one of the most likely survivors among these six players in China's fiercely competitive AI landscape. Their space in LLMs has been recently disrupted by DeepSeek, which has gained significant attention following its recent release of more cost-effective models, including its reasoning-focused R1.
Despite its recent sudden leap to fame, DeepSeek isn't considered one of the six AI tigers in LLMs. Among the other five –&nbsp;MiniMax,&nbsp;Moonshot,&nbsp;Baichuan,&nbsp;StepFun&nbsp;and&nbsp;01.AI&nbsp;– two have already signaled a strategic shift away from foundational model development, of which LLMs are a subset. 01.AI, founded by AI pioneer and prominent venture capitalist and former Google China chief Lee Kai-Fu, has indicated it will cease investing in the development of foundational models, which demands substantial investment in AI chips and R&amp;D.
Instead, these companies are pivoting toward developing applications based on foundational models developed by other companies like DeepSeek. Baichuan, founded by Wang Xiaochuan, former CEO of search engine Sougou, has similarly indicated a strategic pivot, focusing on healthcare applications rather than continuing investment in foundational models.
While the other three companies haven't commented on their strategies lately, Zhipu AI stands out with its unequivocal commitment to foundational model development. The company has recently doubled down on this approach, launching a general-purpose AI agent in March, powered by its proprietary GLM model. It has also&nbsp;<a href="https://www.reuters.com/technology/artificial-intelligence/chinas-zhipu-ai-launches-free-ai-agent-intensifying-domestic-tech-race-2025-03-31/">taken the additional step</a>&nbsp;of open-sourcing its foundational models, similar to DeepSeek.
<h4 class="wp-block-heading">State backing</h4>
Among the foundational AI tigers, Zhipu has demonstrated a noteworthy ability to raise funds. While its peers have been quiet on that front over the past year, Zhipu has emerged as an investor favorite, securing at least 2 billion yuan ($276 million) in fresh funds this year alone.
The fundraising streak began in early March when the municipal government of Hangzhou, capital of Zhejiang province, emerged as the lead investor in a 1 billion yuan funding round. This was followed by investments from three other Chinese cities: Zhuhai in Guangdong province contributed 500 million yuan; Chengdu, capital of Sichuan province, invested 300 million yuan; and most recently, the Beijing municipal government provided 200 million yuan.
The recent funding wave is noteworthy for being led by government-backed sources, as China moves aggressively to develop the sector. Zhipu's seizing on that largess marks a shift for the company from its previous reliance on private capital.
Founded in 2019 by Tsinghua University alumni Tang Jie and Zhang Peng, Zhipu AI began within the university's walls and was later spun off. Its early funding rounds attracted prominent private investors like HongShan – formerly Sequoia China – and Chinese internet giants such as Alibaba and Tencent. Its roots at China's most famous sciences university may be at least partly behind the recent flood of state capital to the company.
Zhipu was among China's pioneers in LLM development, founded before OpenAI's transformative release of ChatGPT in late 2022. The ChatGPT launch sparked an AI rush in China, leading to the emergence of numerous companies racing to develop Chinese alternatives. All of Zhipu's major competitors were established in this post-ChatGPT era.
The company's financial prowess is evident in its fundraising history. According to research firm RimeData, Zhipu has completed 14 funding rounds since its inception, raising over 9 billion yuan. Its ability to raise so much money, combined with its early focus on LLMs, has given Zhipu a leg up on its competitors in China's intensely competitive AI landscape.
However, Zhipu's real competition isn't coming from other AI startups, but rather from tech giants like&nbsp;Alibaba,&nbsp;ByteDance, and&nbsp;Tencent, as well as the fast-rising DeepSeek. While Zhipu boasts strong backing from both public and private sources, such established players command even greater financial resources from their highly profitable core businesses.
While AI commercialization remains in its early stages, the race to capture consumer market share reveals the current state of the market. Zhipu's Qingyan consumer app ranks ninth with 9 million monthly active users, significantly behind market leaders. Alibaba's Quark app leads the pack with 149 million monthly active users, followed by ByteDance's Doubao with 107 million and DeepSeek's 96 million, according to April data from AI product tracker Aicpb.com.
That said, consumer applications aren't Zhipu AI's primary focus. The company has positioned itself more strategically as a provider of customized AI solutions for enterprise clients and government organizations, which tend to be more profitable than consumers.
In China's technology market, government organizations, along with national and local state-owned enterprises, are some of the biggest spenders on software and digital solutions – which could work to Zhipu's advantage due to its strong government connections.
But such heavy government reliance carries its own risks. A cautionary tale can be found in the fate of the four "AI dragons" from the pre-ChatGPT era, when AI was primarily associated with recognition technology, in this case involving computer vision.
The four AI dragons –&nbsp;SenseTime&nbsp;(0020.HK),&nbsp;Megvii,&nbsp;CloudWalk&nbsp;(688327.SH) and&nbsp;Yitu&nbsp;–primarily built their businesses on government work, providing surveillance systems powered by computer vision technology. However, these companies have largely faded from prominence following government spending cuts in surveillance-related projects.
Unable to diversify their customer base or expand into new applications, these once-prominent AI companies now find themselves struggling with dwindling business and mounting losses. In a nod to that reality, SenseTime&nbsp;<a href="https://thebambooworks.com/time-for-a-shift-sensetime-formalizes-pivot-to-generative-ai/">has recently been</a>&nbsp;rapidly shifting its business away from its recognition technology roots, and moving towards foundational models with better commercial potential.
At the end of the day, Zhipu's substantial financial resources position it as a likely survivor as it competes against tech giants in China's fast-evolving AI landscape. Still, it faces a critical challenge as it prepares to become first in its class to list: demonstrating to investors it can generate sustainable revenue from its proprietary products and services.

Asia

Equities

IPOs

Opinion

Tech

The Race To Go Public Among New Gen Chinese 'AI Tigers'

D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $25 price target.

URGN

D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay," at the <a href="https://pr.report/ab65">2025 Genetic Toxicology Association Annual Meeting</a>, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ("API") in IGC-AD1, the Company's investigational drug for Alzheimer's disease.
Part of the FDA's battery of safety requirements is to show that APIs are safe for human consumption, including that they do not alter or mutate genes. IGC completed this requirement and is now able to show that the APIs in IGC-AD1 are safe and do not alter genes.

Biotech

General

IGC Pharma Presents Its Latest Scientific Poster, Titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," At The 2025 Genetic Toxicology Association Annual Meeting

Shares of Chinese electric vehicle (EV) maker XPeng Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) surged 7.7% to $21.15 Monday morning following news that the U.S. and China reached a temporary truce in their ongoing trade dispute, agreeing to significantly roll back tariffs on <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">most goods for 90 days</a>.
What To Know: XPeng, an EV manufacturer based in Guangzhou, stands to benefit directly from the <a href="https://www.benzinga.com/topic/tariffs">tariff</a> reduction. The company has been aggressively expanding its footprint in Europe and exploring entry into the North American market.
With tariffs now lowered from 125% to just 10% on most categories, XPeng's cost structure for potential U.S. exports and imported U.S. components likely improves considerably.
Moreover, China's suspension of non-tariff countermeasures, including sanctions and export restrictions on high-tech materials, could ease XPeng's access to advanced semiconductors and batteries, critical to its XNGP autonomous driving platform and upcoming G6 and X9 models.
The easing of geopolitical tensions could also boost investor confidence in XPeng's international strategy and alleviates risks tied to supply chain disruptions and trade barriers.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/05/45327340/3-best-energy-stocks-to-buy-right-now">3 Best Energy Stocks To Buy Right Now</a>
<h2 class="wp-block-heading">How To Buy XPEV Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in XPeng&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, XPEV has a 52-week high of $27.16 and a 52-week low of $6.60.

XPEV

XPeng (XPEV) Stock Surges On US–China Tariff Easing: What's Going On?

MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.79 percent. This is a 93.08 percent increase over losses of $(10.26) per share from the same period last year.

MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate

Jianzhi Education Technology Group Company Limited ("Jianzhi") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>), a leading provider of digital educational content in China, today announced it had partnered with China Telecom, one of the world's largest and most influential integrated communications and technology providers. This major collaboration represents a critical step forward in integrating Jianzhi's robust education platforms into China Telecom's expansive cloud center infrastructure.
Following extensive negotiations between the two organizations, this landmark collaboration aims to reshape the future of education by embedding cutting-edge AI-generated content (AIGC) and digital human technologies into every facet of the learning experience.
China Telecom, a Fortune Global 500 company with over 425 million mobile subscribers and operating revenues amounting to US$72.5 billion in 2024, brings immense infrastructure strength, technical support, and national reach to the project. By aligning with&nbsp;Jianzhi, China Telecom will further extend its strategic presence in the digital education space through seamless cloud-based delivery. Jianzhi's cloud-ready educational content and platforms will support the joint development of new cloud-native applications and services tailored to the needs of learners and institutions nationwide.

Jianzhi Education Technology Announces It Had Partnered With China Telecom, Collaboration Aims To Reshape The Future Of Education By Embedding Cutting-Edge AI-Generated Content And Digital Human Technologies Into The Learning Experience

CORRECTION: NRG Energy Q1 Adj. EPS $2.62 Beats $1.49 Estimate, Sales $8.59B Beat $7.83B Estimate

WIIM

RMTI

Rockwell Medical shares are trading higher after the company reported better-than-expected Q1 financial results.

MEGL

Magic Empire Global shares are trading lower after the company announced it filed a prospectus for the offer and sale of up to 15 million shares.

Guggenheim analyst Curry Baker maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and lowers the price target from $61 to $60.

DKNG

Guggenheim Maintains Buy on DraftKings, Lowers Price Target to $60

Management

NWBI

Northwest Bancshares Announces Timothy B. Fannin Has Stepped Down As Board Chair, And Has Been Succeeded By Vice Chair Timothy M. Hunter

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst Richard Close downgraded DocGo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) from Buy to Hold and lowered the price target from $5 to $1.45. DocGo shares closed at $1.40 on Friday. <a href="https://www.benzinga.com/quote/dcgo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research analyst Michael Petusky downgraded the rating for ModivCare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) from Outperform to Market Perform. ModivCare shares closed at $1.17 on Friday. <a href="https://www.benzinga.com/quote/modv/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ekaterina Knyazkova downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and cut the price target from $45 to $30. Amphastar Pharma shares closed at $24.11 on Friday. <a href="https://www.benzinga.com/quote/amph/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Zhihan Ma downgraded the rating for Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) from Market Perform to Underperform and lowered the price target from $97 to $82. Target shares closed at $96.40 on Friday. <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Stephen Laszczyk downgraded Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Buy to Neutral and slashed the price target from $35 to $28. Warner Music shares closed at $27.36 on Friday. <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TGT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-1024x577.png" alt="" class="wp-image-911928" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Downgrades

AMPH

DCGO

MODV

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Superior Industries International shares are trading lower after the company reported worse-than-expected Q1 EPS results and announced it is withdrawing its FY25 guidance.

Inter &amp; Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTR#NASDAQ">INTR</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.12 by 8.33 percent. This is a 22.22 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $313.81 million which missed the analyst consensus estimate of $327.02 million by 4.04 percent. This is a 10.88 percent increase over sales of $283.02 million the same period last year.

Earnings Misses

INTR

Inter & Co Q1 GAAP EPS $0.11 Misses $0.12 Estimate, Sales $313.81M Miss $327.02M Estimate

In the face of ongoing trade tensions,&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly contemplating raising the prices for its forthcoming fall iPhone models, while also planning to introduce new features and design changes.
What Happened: The iPhone maker is planning a price hike but is keen to dispel any notion that a possible price increase is tied to U.S. tariffs on Chinese goods, where most of its devices are assembled, according to a <a href="https://www.wsj.com/tech/apple-iphone-price-increase-2eaebb14">report</a> by The Wall Street Journal on Monday.
Facing supply chain pressures, Apple is considering raising iPhone prices to protect profits, while seeking non-tariff reasons to justify the hike, though new feature details remain unclear. Notably, the company is preparing to launch new iPhones this fall, which will include design updates such as an ultrathin profile.
CEO Tim Cook has been navigating the U.S.-China trade tensions, which threaten Apple's supply chain. In response, he has increased inventory levels and moved some U.S.-bound manufacturing to India. However, production of Apple's high-end models like the Pro and Pro Max will largely remain in Chinese factories, as India's infrastructure and technical capacity are not yet advanced enough to support large-scale production on par with China's current capabilities, sources told the publication.
Apple is also exploring the possibility of shifting some iPhone production to the U.S., a move that could take several years. In the meantime, its shift toward manufacturing smartphones in India for export to the U.S. is expected to gain momentum.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45343504/judge-halts-arizona-land-transfer-to-rio-tinto-citing-native-appeal" target="_blank" rel="noreferrer noopener">Judge Halts Arizona Land Transfer To Rio Tinto Citing Native Appeal</a>
Why It Matters: Apple&#8217;s potential price hike comes amid a series of strategic moves and product innovations. Earlier in May, Apple&#8217;s CEO, Tim Cook, discussed the possibility of <a href="https://www.benzinga.com/markets/25/05/45162929/tim-cook-tells-commerce-secretary-lutnick-how-apple-could-bring-iphone-manufacturing-to-us">relocating iPhone</a> production to the U.S. with U.S. Commerce Secretary Howard Lutnick. This was followed by the news of Apple bracing for a $900 million <a href="https://www.benzinga.com/markets/25/05/45185355/apple-braces-for-900-million-tariff-impact-tim-cook-discusses-potential-iphone-manufacturing-shift-to-us-with-lutnick-and-more-this-week-in-appleverse">tariff impact</a>, as revealed by Cook during the company&#8217;s fiscal second-quarter earnings call.
Notably, Apple is reportedly planning a <a href="https://www.benzinga.com/tech/25/05/45338324/apples-2027-vision-foldable-iphones-smart-glasses-and-ai-innovations">significant year </a>in 2027, with plans to introduce a range of innovative devices and features, including a foldable iPhone and smart glasses. These developments highlight Apple&#8217;s ongoing efforts to navigate trade tensions while maintaining its commitment to innovation and customer satisfaction.
Despite these strategies, Apple may still find it challenging to counterbalance China tariff costs solely through supplier savings, potentially affecting its profit margin unless it can increase prices. However, executives are wary about attributing price increases to tariffs, after the White House slammed Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), displaying tariffs beside its product prices and calling it a &#8216;hostile act&#8217;.
Apple holds a momentum rating of 49.76% and a quality rating of 82.46%, according to&nbsp;<a href="https://www.benzinga.com/quote/AAPL" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
Apple stock has declined 18.59% during the year-to-date period.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45338404/charlie-mungers-financial-success-advice-i-avoided-standard-ways-of-failing-because-my-game-in-life-was-always-to-avoid-all-standard-ways-of-failing" target="_blank" rel="noreferrer noopener">Charlie Munger&#8217;s Financial Success Advice: &#8216;I Avoided Standard Ways Of Failing, Because My Game in Life Was Always To Avoid All Standard Ways of Failing&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AAPL

AMZN

Apple May Hike iPhone Prices This Fall, Steering Clear Of Tariff Blame: Report

CTMX

CytomX Therapeutics shares are trading higher. The company announced a $100 million offering of 76.9 million shares at $1.30 per share.

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya&nbsp;(somapacitan) in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and idiopathic short stature (ISS) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">under one trial protocol</a>.
In REAL8, pre-pubertal children with NS, TS, or ISS were randomized to receive either once-weekly Sogroya&nbsp;(somapacitan) 0.24 mg/kg/week or once-daily somatropin 0.050 mg/kg/day.
Children born SGA were <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916003" rel="noreferrer noopener">randomized</a> to receive either somapacitan 0.24 mg/kg/week, a low dose of somatropin 0.035 mg/kg/day, or a high dose of somatropin 0.067 mg/kg/day.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80" rel="noreferrer noopener">Trump&#8217;s New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&amp;J Fall In Premarket</a>
The trial showed that once-weekly Sogroya was non-inferior to the once-daily growth hormone Norditropin&nbsp;(somatropin) in improving yearly growth rate (as measured by height velocity or HV at Week 52).
In addition, once-weekly Sogroya was superior to daily growth hormone in children with NS and to lower doses of daily growth hormone in children born SGA.
REAL8 data showed that Sogroya&nbsp;was well-tolerated, with no safety or tolerability issues identified compared to once-daily growth hormone.
Results from the Turner syndrome (TS) sub-study of REAL8 will be available later this year.
The REAL8 trial achieved its primary endpoints for the first three sub-studies, demonstrating that once-weekly Sogroya&nbsp;was non-inferior to once-daily growth hormone treatment at Week 52 across the three indications presented:
<ul class="wp-block-list">
<li>In children born SGA, Sogroya&nbsp;demonstrated superior estimated mean HV when compared with a lower dose (0.035 mg/kg/day) of somatropin (11.0 vs 9.4 cm/year) and non-inferior estimated mean HV when compared with a higher dose (0.067 mg/kg/day) of somatropin (11.0 vs 11.1 cm/year).</li>
<li>Sogroya&nbsp;demonstrated superior estimated mean HV in children with NS compared with somatropin (10.4 vs 9.2 cm/year).</li>
<li>Sogroya&nbsp;demonstrated non-inferior estimated mean HV in children with ISS compared with daily somatropin (10.5 vs 10.5 cm/year).</li>
<li>In April 2025, based on the data from REAL8 and REAL9, the three indications (SGA, NS, and ISS) were submitted for regulatory review in both the EU and the U.S.</li>
</ul>
Price Action: NVO stock is down 3.00% to $63.80 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45328107/shopify-shows-strong-global-momentum-but-guidance-raises-questions-on-profitability-path" target="_blank" rel="noreferrer noopener">Shopify Shows Strong Global Momentum, But Guidance Raises Questions On Profitability Path</a></li>
</ul>
Image via Shutterstock

Large Cap

Health Care

Movers

Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

Guggenheim analyst Debjit Chattopadhyay maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and lowers the price target from $55 to $45.

NTLA

Guggenheim Maintains Buy on Intellia Therapeutics, Lowers Price Target to $45

Press Releases

Paysafe Reports Third Quarter 2024 Results; Reaffirms Full Year Outlook

Small Cap

Copa Airlines Unveils New Support for Key Alternative Payment Methods in Partnership with UATP

Paysafe Expands Payment Options Business to Brazil

Global Bettors Demand Payment Choice, Speed, and Security in Play

Paysafe Announces Agreement to Sell Direct Marketing Payment Processing Business Line

Paysafe to Release Fourth Quarter and Full Year 2024 Earnings Results on March 4

Paysafe Reports Fourth Quarter and Full Year 2024 Results

Paysafe to Participate in the Wolfe Research FinTech Forum on March 12

Paysafe to Release First Quarter 2025 Earnings Results on May 13

Paysafe and Fiserv Strengthen Partnership to Drive SMB Growth with Enhanced Capital Access, Fraud Protection, and New Digital Wallet Solution

GOLLQ

JAPSY

QABSY

QUBSF

TKHVY

TSX:AC

TYO:9201

AppTech Payments

AvidXchange Holdings, Inc. - Common Stock

AvidXchange Holdings

Cass Information Systems, Inc - Common Stock

Cass Information Sys

Cantaloupe

Currenc Group

DLocal

Evertec

DigiAsia

Flywire Corporation - Voting Common Stock

Flywire

International Money Express, Inc. - Common Stock

International Money

Lesaka Technologies

Marqeta

NCR Atleos

OLB Group

PagSeguro Digital Ltd. Class A Common Shares

PagSeguro Digital

Paymentus Holdings, Inc. Class A Common Stock

Paymentus Holdings

Payoneer Global

PaySign

Priority Technology Holdings, Inc. - Common Stock

Priority Tech Holdings

Repay Holdings Corporation - Class A Common Stock

Repay Holdings

Ryvyl

Sezzle

StoneCo

Usio

Western Union

Susquehanna

B of A Securities

RBC Capital

BTIG

<h2 class="wp-block-heading">블록에 등장한 신규 기업들</h2>
팜켐(OTC:<a class="ticker" href="https://www.benzinga.com/stock/PCHM#OTC">PCHM</a>), 약물 감지 땀 패치의 대표 기업이 전략적 대안을 모색하고 있다(즉, 인수합병 또는 매각). 이사회는 지금까지 은행가를 고용하는 것보다 독자적으로 상황을 처리할 수 있다고 자신감을 나타냈다. 관심 있는 인수자는 <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">공식 데이터룸</a>에 접근할 수 있다.
이번 주 경매 블록의 다른 아이템들:
<ul>
<li>온타리오 교원연기금(Ontario Teachers&#8217; Pension Plan)이 라자(Lazard)를 고용하여 컴플라이언스 소프트웨어 회사 미트라테크(Mitratech)의 매각 프로세스를 운영하도록 했다. 로이터는 거래 규모가 약 40억 달러에 이를 것으로 추정하고 있다.</li>
<li>페이세이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>)가 2020년에 <a href="https://www.benzinga.com/news/20/12/18678982/paysafe-goes-public-again-in-spac-deal-what-investors-should-know">SPAC을 통해 상장된</a> 것을 기억하자. 현재, 블룸버그에 따르면 <a href="https://www.bloomberg.com/news/articles/2025-02-06/paysafe-is-said-to-weigh-sale-after-getting-takeover-interest?srnd=phx-deals">매각 대상</a>이 되고 있다. 억만장자 빌 폴리(Bill Foley)가 지원하는 이 회사는 인수 관심을 받고 있다.</li>
<li>스위스에 본사를 둔 뱅크 J. 사프라 사라신(Bank J. Safra Sarasin)은 덴마크의 삭소 은행에 대한 인수 제안을 검토 중이다. 이는 <a href="https://www.bloomberg.com/news/articles/2025-02-03/safra-sarasin-is-said-to-explore-deal-for-denmark-s-saxo-bank?srnd=phx-deals">블룸버그</a>에 의해 보도되었다.</li>
</ul>
<h2 class="wp-block-heading">블록에서의 업데이트</h2>
<ul>
<li>베리타스 캐피털(Veritas Capital)은 월스트리트 데이터 제공업체 던 앤 브래드스트리트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNB#NYSE">DNB</a>)를 인수하기 위해 접촉 중이다. <a href="https://www.bloomberg.com/news/articles/2025-02-07/veritas-is-said-in-talks-to-acquire-data-firm-dun-bradstreet?srnd=phx-deals">블룸버그</a>에 따르면, 던 앤 브래드스트리트의 시장 가치는 49억 달러이다.</li>
<li>바슈 + 롬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>)은 바슈 헬스 컴퍼니스(Bausch Health Companies Inc.)와의 &#8220;완전 분리&#8221;를 고려했다. 잠재적 구매자들과의 협상 후, 그 과정은 거래로 이어지지 않았다. 이 회사는 완전한 분리를 목표로 하고 있음을 확인했다. 2024년 전체 연간 수익은 2월 19일에 발표될 예정이다.</li>
<li>KKR &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)는 일본 기술 그룹 후지 소프트를 인수하려고 한다. 이 사모펀드는 경쟁사 베인 캐피털를 제치기 위해 제안을 약 43억 달러로 인상했다.</li>
<li>베인은 후지 소프트 거래가 성사되지 않을 경우를 대비해 다른 거래를 진행 중이다. <a href="https://www.bloomberg.com/news/articles/2025-02-06/bain-is-said-to-near-3-billion-deal-for-mitsubishi-pharma-unit?srnd=phx-deals">블룸버그에 따르면</a>, 이 회사는 미츠비시 케미컬 홀딩스(TYO:<a class="ticker" href="https://www.benzinga.com/stock/TYO:4188#TYO">4188</a>)의 제약 부문을 인수하기 위해 거의 33억 달러 이상을 지불할 예정이다.</li>
</ul>
<h2 class="wp-block-heading">블록에서 나온 거래들</h2>
<ul>
<li>한편, 베인 캐피털는 밀라크론(Milacron)의 51% 지분을 <a href="https://www.plasticsnews.com/news/hillenbrand-sells-majority-stake-milacron-bain-capital-287m">인수하기로 합의</a>했다. 밀라크론은 플라스틱 가공 장비 및 서비스 제공업체이며, 힐렌브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>)는 이 지분을 2억 8천7백만 달러에 매각했다.</li>
<li>리버우드 캐피털(Riverwood Capital)은 뮌헨에 본사를 둔 소매업체 및 브랜드 가격 책정 플랫폼 퀵리자드(TASE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/qlrd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for QLRD" data-google-interstitial="false">QLRD</a>)를 약 5천2백만 달러에 인수하기로 합의했다.</li>
<li>TPG는 미국의 상업용 규모의 태양광 발전소 소유업체 알투스 파워(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>)를 약 22억 달러에 인수하기로 합의했다.</li>
<li>또 다른 태양광 관련 거래: 턴/리버 캐피털(Turn/River Capital)은 텍사스 오스틴에 본사를 둔 솔라윈즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>)를 44억 달러에 인수하기로 합의했다. 이는 2월 6일 목요일 주가 종가 대비 35% 프리미엄이다.</li>
<li>몬트리올에 본사를 둔 발소프트(Valsoft)는 코아츄 매니지먼트(Coatue Management)와 바이킹 글로벌 인베스터(Viking Global Investors)의 지원을 받아 브라질의 클라우드 기반 공증인 관리 소프트웨어 제공업체 VHL 시스테마스(VHL Sistemas)를 인수했다.</li>
<li>BCI, 캐나다 자산 관리 회사가 룩셈부르크에 본사를 둔 투자사 BBGI 글로벌 인프(LSE:BBGIB)를 약 10억 파운드 (12억 4천만 달러)에 인수하기로 합의했다.</li>
<li>EP 글로벌 코머스, 억만장자 다니엘 크레틴스키(Daniel Kretinsky)가 지원하는 회사가 메트로를 20억 유로 (27억 6천만 달러)로 <a href="https://www.bloomberg.com/news/articles/2025-02-06/czech-billionaire-kretinsky-seeks-to-take-metro-private-again?srnd=phx-deals" target="_blank" rel="noopener">인수</a>했다. 이는 독일 뒤셀도르프에 본사를 두고 있다.</li>
<li>데이터브릭스, 620억 달러로 평가된 회사가 블레이드브릿지(BladeBridge)를 <a href="https://www.infoworld.com/article/3817328/databricks-acquires-bladebridge-to-aid-data-warehouse-migrations.html" target="_blank" rel="noopener">인수</a>하여 기업 데이터 웨어하우스 마이그레이션을 강화했다.</li>
<li>JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)은 독일의 세코노미 AG 인수에 대한 관심을 되살렸다고 한다. 이 중국 전자상거래 거인은 2023년에 <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43496221/jd-coms-stock-dips-as-ceconomy-deal-heats-up-in-germany-is-the-e-commerce-king-eyeing-expansion">독일 소매업체에 대한 관심을 마지막</a>으로 나타냈다.</li>
<li>닛산 자동차(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>)의 CEO 우치다 마코토(Makoto Uchida)는 혼다 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>)의 CEO 미베 토시히로(Toshihiro Mibe)에게 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%8B%9B%EC%82%B0-%EC%9E%90%EB%8F%99%EC%B0%A8-ceo-%ED%98%BC%EB%8B%A4-%EC%9E%90%EB%8F%99%EC%B0%A8%EC%97%90-%ED%95%A9%EB%B3%91-%ED%98%91%EC%83%81-%EC%A2%85%EB%A3%8C%EB%A5%BC-%ED%86%B5%EB%B3%B4/" target="_blank" rel="noopener">잠재적 합병 논의를 종료하겠다는 의사를 통보</a>했다.</li>
<li>브룩필드(Brookfield)는 휴스턴에 본사를 둔 전기 열 및 센싱 솔루션 제공업체 케멜렉스(Chemelex)를 17억 달러에 인수하는 거래를 완료했다. 골드만삭스는 엔벤트 일렉트릭(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>)의 매각 측에서 자문을 맡았다.</li>
<li>코트 스퀘어 캐피털 파트너스와 윈드로즈 헬스 인베스터스(WindRose Health Investors)는 텍사스 프리스코에 본사를 둔 주입 회사 솔레오 헬스(Soleo Health)의 11억 달러 인수 거래를 완료했다.</li>
</ul>
<h2 class="wp-block-heading">파산 블록</h2>
판사 크리스토퍼 로페즈(Christopher Lopez)는 알렉스 존스(Alex Jones)의 미디어 회사 인포워스(Infowars)의 두 번째 경매 시도를 용이하게 하는 거래를 거부했다. NPR에 따르면 이 판결은 조에게 또 다른 임시 구제를 제공하지만, 샌디 훅 가족들이 거의 7년 전 부당성 손해배상으로 판결된 13억 달러를 회수하기 위한 노력을 지연시킨다.
로페즈 판사는 인포워스의 모회사인 프리 스피치 시스템(FSS)이 더 이상 파산 상태가 아니기 때문에 거래를 승인할 수 없다고 설명했다. 즉, 그의 판단에 따라 자산은 판매될 수 없으며, 오직 조의 회사 소유 지분만 경매에 부쳐질 수 있다. 그러나 판사는 또한 <a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars">이전 제안</a>을 차단했다. 이 제안은 풍자 웹사이트 디 어니언(The Onion)이 샌디 훅 희생자 가족들과 협력하여 인포워스에 입찰한 것이었다.
앞으로 로페즈는 모든 자산 판매는 간단한 현금 거래여야 한다고 강조했다. 이번 결정으로 손해배상 회수 및 조의 플랫폼 해체 가능성에 대한 경로는 여전히 불확실하다.
TGI 프라이데이는 11장소를 포함하여 19개의 추가 매장을 파산 보호 챕터 11 절차의 일환으로 매각했다. 캘리포니아 프리몬트에 본사를 둔 야다브 엔터프라이즈가 300만 달러의 부채로 16개 매장을 인수하고, 슈가로프 호스피텔리티, 전 TGI 프라이데이의 CEO 레이 블란셰트(Ray Blanchette) 소유의 회사가 3개 매장을 10만 달러에 인수하고 있다.
<h2 class="wp-block-heading">블록에서의 노트</h2>
규모 vs 범위: 이번 주 베인 캐피털은 미디어 부문에서의 트렌드를 지적했다.
미디어 거래가 &#8220;주로 산업 간 거래&#8221;가 되고 있다. 베인의 <a href="https://www.bain.com/insights/media-and-entertainment-m-and-a-report-2025/">분석</a>에 따르면, 딜로직(Dealogic)의 데이터를 사용하여 2024년 1~3분기 동안 모든 미디어 산업 M&amp;A의 절반 이상이 목표 또는 인수자가 자사 산업 외부에 있었던 것으로 나타났다.
여기 몇 가지 주목할 만한 사항들이 있다. 베인의 파트너인 니콜 마군, 매트 키스 및 알렉스 이건이 언급했다:
<ul>
<li>과거에는 월트 디즈니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)의 거래 대부분이 &#8220;규모&#8221; (즉, 2006년 Pixar 인수 및 2019년 21세기 폭스 인수)였으나, 현재는 &#8220;범위 거래&#8221;의 비중이 높아지고 있다. 예를 들어, 지난해 디즈니는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41052867/disneys-streaming-surge-epic-games-deal-among-key-growth-drivers-says-analyst">포트나이트의 제작사</a> 에픽 게임즈에 투자했다.</li>
<li>소니 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>)는 알라모 드래프트하우스(Alamo Drafthouse)라는 극장-저녁 식사 체인을 인수했다.</li>
<li>기업들은 또한 지속 가능한 IP를 위한 거래를 진행하고 있다: 소니 뮤직은 마이클 잭슨의 <a href="https://www.benzinga.com/general/entertainment/24/08/40515995/michael-jacksons-1-5b-catalog-lands-court-approval-for-sale-thriller-for-sony">음악 및 저작권 카탈로그</a>의 절반을 인수했다.</li>
<li>팝하우스 엔터테인먼트(Pophouse Entertainment)는 키스(Kiss)의 카탈로그와 <a href="https://www.benzinga.com/general/entertainment/24/04/38116031/sealed-with-a-kiss-rock-band-sells-legacy-for-300m-who-did-gene-simmons-get-into-bed-with">밴드 멤버의 초상권</a>를 인수했다.</li>
<li>사모펀드들은 품질 있는 IP를 보유한 소규모 제작 스튜디오에 투자하고 있다. 예를 들어, 레드버드(Redbird)는 All3Media를 인수하여 영상 분야에서 지속적인 우위를 확보하고자 했다.</li>
</ul>
위험이 있을까? &#8220;산업 간 미디어 M&amp;A에서 인수자는 이러한 거래가 다른 유형의 실사를 요구한다는 것을 빠르게 배운다&#8221;고 베인의 파트너들이 말한다. &#8220;첫째, 인수자는 목표 산업에 덜 익숙할 가능성이 높다. 또한, 범위 거래에 내재된 수익 시너지는 비용 시너지보다 실현하고 평가하기가 더 어렵다.&#8221;
지난주 딜 디스패치의 에디션은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%84%B8%EC%9D%B4%EC%A7%80%EC%99%80-%EC%8B%A4%EB%B2%84%EC%8A%A4%EA%B0%80-%EB%A7%A4%EA%B0%81-%EC%A4%91-%EB%AF%B8%EC%8A%A4%ED%84%B0%EB%B9%84%EC%8A%A4/" target="_blank" rel="noopener">여기를 클릭하세요.</a>
이미지는 Shutterstock의 사진을 사용하여 생성되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일 오전(현지 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자들의 관심을 끌 수 있는 주식 중 일부는 다음과 같다:
<ul>
<li>월가는 홈 디포(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>)가 개장 전에 분기별 이익을 주당 4.50달러, 매출 433억 8천만 달러로 보고할 것으로 예상하고 있다. 홈디포 주가는 시간외 거래에서 0.2% 상승한 346.59달러를 기록했다.</li>
<li>럼블온(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>)은 2분기 매출은 2,250만 달러로 전 분기 대비 27% 증가했다. Benzinga Pro의 데이터에 따르면 매출 수치는 월가의 컨센서스 추정치인 1,969만 달러를 넘어섰다. 이 회사는 주당 13센트의 손실을 보고했는데, 이는 월가의 컨센서스인 주당 15센트의 손실을 능가하는 것이다. 럼블의 주식은 월요일에 0.3% 하락한 3.42달러로 마감했다.</li>
<li>분석가들은 페이세이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>)가 4억 2,429만 달러의 매출에 주당 8센트의 분기 수익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 개장 전에 실적을 발표할 예정이다. 페이세이프의 주식은 시간외 거래에서 2.6% 상승한 19.86달러를 기록했다.</li>
</ul>
여기에서 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener" data-google-interstitial="false">프리마켓 시황</a>을 확인하세요.
<ul>
<li>카이버나 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>)는 진행성 중증 근무력증 치료에 사용되는 KYV-101에 대해 미국 FDA RMAT 지정을 받았다고 밝혔다. 카이버나 테라퓨틱스의 주가는 시간외 거래에서 2.9% 상승한 6.72달러를 기록했다.</li>
<li>분석가들은 XP(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>)가 시장 마감 후 7억 7,039만 달러의 매출과 주당 36센트의 분기 이익을 기록할 것으로 예상한다. XP의 주가는 월요일에 0.2% 하락한 18.03달러로 마감했다.</li>
</ul>
Photo courtesy: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Paysafe

뉴스

에 대한 최신 뉴스 Paysafe (NYSE:PSFE) 주식

토요일, 2월 08, 2025

화요일, 8월 13, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌